Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EMA approves isatuximab subcutaneous formulation via OBI for patients with myeloma

On June 8, 2026, the European Medicines Agency (EMA) granted approval to isatuximab subcutaneous (SC) in combination with standard-of-care regimens…

Read More

FDA approves pivekimab sunirine for adult patients with BPDCN

On May 27, 2026, the U.S. Food and Drug Administration (FDA) approved pivekimab sunirine (PVEK) for adults with blastic plasmacytoid…

Read More

The updated ASH guidelines for treating newly diagnosed AML in older adults

A feature article focusing on the recent updates to the American Society of Hematology guidelines for older adults with newly…

Read More

FDA approves all-oral DEC-C plus venetoclax for patients with newly diagnosed AML ineligible for intensive chemotherapy

On May 13, 2026, the U.S. Food and Drug Administration (FDA) approved an all-oral regimen of decitabine–cedazuridine (DEC-C; ASTX727) plus…

Read More

FDA grants accelerated approval to sonrotoclax for relapsed/refractory MCL

On May 13, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax for adults with relapsed/refractory…

Read More

The emerging role of hepcidin modulation in polycythemia vera

We’re pleased to share a feature article focusing on the potential of hepcidin modulating agents in polycythemia vera.

Read More

Optimizing the use of GPRC5D-targeted therapies in multiple myeloma care

VJHemOnc is excited to share this feature exploring the optimization of GPRC5D therapies in multiple myeloma.

Read More

Editors’ Picks: Top Abstracts from the 2026 EBMT-EHA CAR-T Meeting

  VJHemOnc is thrilled to share our top picks from the 2026 EBMT-EHA CAR-T Meeting, featuring expert perspectives on the…

Read More

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals